EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY 4.0

STAT6 gain-of-function disease: p.D519N is a new disease-causing variant that responds well to dupilumab treatment

Simran Samra, Eleanor Cook, Jessica Wilson, Mehul Sharma, Liam Golding, David T Yao, Rebecca A Marsh, Stuart E Turvey

Journal of Allergy and Clinical Immunology: Global · 2025-08 · 4 (3) · 100494

DOI: 10.1016/j.jacig.2025.100494 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Journal of Allergy and Clinical Immunology: Global, 2025-08. Verfasst von Simran Samra und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, British Columbia Children's Hospital, The University of British Columbia, Vancouver, British Columbia, Canada. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 10 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Genome British Columbia, University of British Columbia, Canada Research Chairs.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

This case report presents a new genetic variant that causes STAT6 gain-of-function disease in 2 patients, expands the clinical phenotype of STAT6 gain-of-function disease, and describes its authors' success in using therapeutics to manage this rare disease.

Schlagwörter

Stichwörter der Autor:innen

STAT6 gain-of-function diseaseinborn errors of immunitymonogenic allergic disorderprimary atopic disorder

Autor:innen und Institutionen

  • Department of Pediatrics, British Columbia Children's Hospital, The University of British Columbia, Vancouver, British Columbia, Canada.
  • Experimental Medicine Program, Department of Medicine, The University of British Columbia, Vancouver, British Columbia, Canada.
  • Division of Bone Marrow Transplant and Immune Deficiency, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio.
  • Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, Ohio.
  • Kids Cancer Centre, Sydney Children's Hospital, Sydney, Australia.
  • Pharming Healthcare, Inc, Warren, NJ.

Förderung

  • Genome British Columbia
  • University of British Columbia
  • Canada Research Chairs
  • Canadian Institutes of Health Research

Zitieren

APA

Samra, S., Cook, E., Wilson, J., Sharma, M., Golding, L., Yao, D. T., Marsh, R. A., & Turvey, S. E. (2025). STAT6 gain-of-function disease: p.D519N is a new disease-causing variant that responds well to dupilumab treatment. Journal of Allergy and Clinical Immunology: Global, 4(3), 100494. https://doi.org/10.1016/j.jacig.2025.100494

Vancouver

Samra S, Cook E, Wilson J, Sharma M, Golding L, Yao DT, et al. STAT6 gain-of-function disease: p.D519N is a new disease-causing variant that responds well to dupilumab treatment. Journal of Allergy and Clinical Immunology: Global. 2025;4(3):100494. doi:10.1016/j.jacig.2025.100494

BibTeX
@article{Samra2025,
  author = {Samra, Simran and Cook, Eleanor and Wilson, Jessica and Sharma, Mehul and Golding, Liam and Yao, David T and Marsh, Rebecca A and Turvey, Stuart E},
  title = {STAT6 gain-of-function disease: p.D519N is a new disease-causing variant that responds well to dupilumab treatment},
  journal = {Journal of Allergy and Clinical Immunology: Global},
  year = {2025},
  volume = {4},
  number = {3},
  pages = {100494},
  doi = {10.1016/j.jacig.2025.100494}
}
Kostenlos starten →